Temasek Holdings’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Temasek Holdings’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,588,863	Closed	-$96.3M	–	109
2023 Q4	$96.3M	Sell	9,588,863 -313,077	-3%	-$1.42M	0.54%	35
2023 Q3	$28.5M	Hold	9,901,940	–	–	0.17%	45
2023 Q2	$37.7M	Hold	9,901,940	–	–	0.22%	40
2023 Q1	$18.4M	Hold	9,901,940	–	–	0.11%	45
2022 Q4	$22.8M	Hold	9,901,940	–	–	0.13%	49
2022 Q3	$31.9M	Hold	9,901,940	–	–	0.19%	46
2022 Q2	$54.5M	Hold	9,901,940	–	–	0.3%	42
2022 Q1	$23.1M	Hold	9,901,940	–	–	0.1%	65
2021 Q4	$59.8M	Hold	9,901,940	–	–	0.22%	53
2021 Q3	$137M	Buy	9,901,940 +9,638,782	+3,663%	+$114M	0.48%	43
2021 Q2	$3.42M	Hold	263,158	–	–	0.01%	86
2021 Q1	$4.05M	Buy	+263,158	New	+$6.21M	0.02%	63

Temasek Holdings's GRCL Position: Q1 2024 in Review

Temasek Holdings sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 9,588,863 shares — an estimated $96.3M sold.

Temasek Holdings first reported a position in GRCL in Q1 2021 and held it in 12 quarters. The position peaked at $137M in Q3 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Temasek Holdings reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Temasek Holdings sold 9,588,863 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $96.3M.
Temasek Holdings first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 12 quarters.
Temasek Holdings's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $137M in Q3 2021.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Temasek Holdings's 13F filing for Q1 2024, filed 15 May 2024.